期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

中国真性红细胞增多症研究现状 被引量：4

Research status of polycythemia vera in China
原文传递
导出
摘要 真性红细胞增多症(PV)是以红细胞增多为主的两系或三系血细胞增高的造血干细胞(HSCs)恶性克隆性疾病。文章对其发病机制、临床特征、疾病进展和治疗选择等在中国的研究现状进行综述,为临床医师精确诊治该疾病奠定基础。 Polycythemia vera is a clonal malignant hematopoietic disorder that results from genetic alterations in hematopoietic stem cells, which is characterized by two or three-line blood cells increase, and mainly by erythrocytosis. This article reviews research situation of PV in China, including pathogenesis, clinical features, disease progression and therapeutic options, which helps clinical specialists to carry out precise diagnosis and treatment.
作者 付莉霞 王颖韶 白洁 FU Li-xia;WANG Ying-shao;BAI Jie(Department of Hematology,the Second Hospital of Tianjin Medical University,Tianjin 300211,China)
机构地区 天津医科大学第二医院血液内科
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2019年第2期127-131,共5页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(81170128) 天津市自然科学基金(16 JCZDJC34500)
关键词 真性红细胞增多症 发病机制 临床特征 疾病进展 治疗选择 polycythemia vera pathogenesis clinical features disease progression therapeutic options
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献9

二级参考文献86

  • 1Lacout C, PisanJ DF, Tulliez M, et al. JAK2V617 expression in mutine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood, 2006; 108 ( 5 ) : 1652 - 1659.
  • 2Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia, 2007 ; 21 (9) : 1952 - 1959.
  • 3Pardanani A, Hood J, Lashol T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia, 2007 ; 21 ( 8 ) : 1658 - 1668.
  • 4Pardanani A, Lashol T, Smith G, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009 ; 23 ( 8 ) : 1441 - 1445.
  • 5Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon- alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 2008 ; 112 ( 8 ) : 3065 - 3072.
  • 6Massaro P, Foa P, Pomati M, et al. Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol, 1997; 56(2) : 126 - 128.
  • 7Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood, 2006 ; 107 ( 8 ) :3339 - 3341.
  • 8Polycythemia vera, Chronic idiopathic myelofibrosis, Acute mye- loid leukaemia. In Pierre R, Imbert M, Thiele J, Brunning R. D, Matutes E, Harris N. L, et al. World Health Organization classification of Tumours. F-69008 lyon: IARC, 2001:32-75.
  • 9XuX, Zhang Q, Luo J, etal. JAK2 (V617F) : Prevalence in a large Chinese hospital population. Blood, 2007 ; 109 ( 1 ) : 339 - 342.
  • 10Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood, 2006; 107(10) : 4139 -4141.

共引文献85

同被引文献17

引证文献4

二级引证文献7

中国实用内科杂志
2019年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部